Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1236 · 2 trials · 1 indication
Number of patients who had an Adverse Event
Ratio reflects Sputum Tumor Necrosis Factor alpha (TNF alpha) at week 6 value divide by baseline value. Baseline is geometric mean of Visit 2 (last value during run-in) and Visit 3 (Randomization).
Ratio reflects Sputum Total Cells at week 6 value divide by baseline value. Baseline is geometric mean of Visit 2 (last value during run-in) and Visit 3 (Randomization).
Ratio reflects Total Urine Desmosine at week 6 value divide by baseline value. Baseline is visit 3(Randomization) value.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| AZD1236 | EXPERIMENTAL | oral tablet, 75 mg, twice daily during 6 weeks |
| Placebo | PLACEBO_COMPARATOR | Dosing to match AZD1236 |
| Name | Type | Description |
|---|---|---|
| AZD1236 | DRUG | oral tablet, 75 mg, twice daily during 6 weeks |
| Placebo | DRUG | Dosing to match AZD1236 |
Inclusion Criteria: * Diagnosis of COPD for 1 month * Men or postmenopausal women * Spirometry values indicating reduced lung function * Smoking history equivalent to using 20 cigarettes a day for 10 years Exclusion Criteria: * Any current respiratory tract disorders other than COPD * Requirement...
AZD1236 is an investigational small molecule developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It was studied in patients aged 40 years and older with COPD, and it has not been approved for any indication. All clinical work to date has focused on the COPD patient population.
AZD1236 targets the enzymes MMP12 and MMP9, two matrix metalloproteinases. It acts as an inhibitor of these targets. MMP12 and MMP9 are associated with airway inflammation and tissue remodeling in respiratory disease, which is the rationale for studying the compound in Chronic Obstructive Pulmonary Disease.
AZD1236 is developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca sponsored both Phase 2 clinical trials of the compound in Chronic Obstructive Pulmonary Disease, one assessing biomarkers and one evaluating safety and tolerability.
AZD1236 is in Phase 2 development. Two Phase 2 trials in Chronic Obstructive Pulmonary Disease have been completed, and no trials are currently active. The compound is investigational and has not been approved by the FDA or any other regulatory agency for marketing.
AZD1236 has been studied in two completed Phase 2 trials. NCT00758706 assessed the effects of AZD1236 on biomarkers in COPD patients across Denmark, Finland, the Netherlands, and Norway. NCT00758459 evaluated safety and tolerability in COPD patients across Bulgaria, Finland, Germany, Hungary, and Slovakia.
The two completed Phase 2 trials of AZD1236 enrolled a total of 129 patients with Chronic Obstructive Pulmonary Disease. NCT00758706 enrolled 55 patients and NCT00758459 enrolled 74 patients. Both studies were randomized, double-blind, and placebo-controlled, and both required participants to be at least 40 years old.